Fig. 1.

Overview of patient status for patients enrolled in the study (N = 243) and included in the full analysis set (N = 236). EGFR epidermal growth factor receptor, NSCLC non-small-cell lung cancer, TKI tyrosine kinase inhibitor. T790M⁺ indicates positive for T790M mutation; T790M⁻ indicates no T790M mutation. ^aIncluding 11 patients identified retrospectively; ^bT790M testing was not performed in 13 patients because no tumor cells were obtained; ^cT790M testing was not performed in eight patients because no tumor cells were obtained